We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hematology Analyzer Evaluated for Cerebrospinal Fluid Testing

By LabMedica International staff writers
Posted on 04 Apr 2012
Print article
One of newest generation hybrid hematology analyzer is equipped with an improved body fluid analysis mode that is suitable for cerebrospinal fluid (CSF) analysis.

The cellular components of CSF have conventionally been enumerated microscopically by using a hemocytometer-counting chamber, but this is labor intensive and time consuming, and maybe replaced by a hematology autoanalyzer.

Laboratory scientists at the Medical University of Vienna (Austria) analyzed a total of 425 consecutive CSF samples sent to the Department of Laboratory Medicine for routine testing. Microscopic cell counts were performed by biomedical technicians using a Fuchs-Rosenthal counting chamber after samples were stained with methyl violet acetic acid.

CSF samples were measured for white blood cells (WBCs) using the body fluid mode of the XE-5000 Hematology Analyzer. By combining fluorescent dye binding and semiconductor laser technology, the XE-5000 (Sysmex Corporation; Kobe, Japan) differentiates between WBCs that are mononuclear cells (MN), including lymphocytes and monocytes and those that are polymorphonuclear cells (PMN), including all types of granulocytes.

For total WBC counts, the proportions of samples correctly classified by the XE-5000 from different groups were: 88% for 0 to 5 WBC/µL in 330 samples; 47% for 6 to10 WBC/µL in 36 samples; 72% for 11 to 50 WBC/µL in 39 samples; 93% for 51 to 200 WBC/µL in15 samples; and 100% for cell counts above 200 WBC/µL. After the two lowest count categories were combined into one range of 0 to10 WBC/µL, matches increased to 95%. For PMN counts in the 0% to 25% group, 37% of samples were misclassified by the XE-5000. Conversely, for samples with microscopic PMN counts of more than 25%, there was a trend toward underestimation by the XE-5000. Mismatches were most pronounced in samples with fewer than 10 WBC/µL.

The authors concluded that based on the results of their study, they felt confident in recommending the XE-5000 as a reliable WBC counter for CSF, even for samples with low WBC counts, which comprise most laboratory admissions. It was previously recommended that all samples with cell counts of less than 5 and more than 20 WBC/µL on the XE-5000 be manually recounted, but the authors propose selecting samples for microscopic rework based on their DIFF channel scattergrams rather than predefined WBC count results. However, it cannot be recommended as a suitable alternative for manual differential cytological workup. The study was published in the February 2012 edition of the journal Archives of Pathology & Laboratory Medicine.

Related Links:

Medical University of Vienna
Sysmex Corporation



New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.